Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update regarding its clinical development programs, manufacturing and strategy for bringing its Oncoprex(TM) immunogene therapy to market. A corporate presentation is available on GNPX’s website which details anticipated milestones and future guidance for the company. “These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most,” Genprex chairman and chief executive officer Rodney Varner stated in the news release. “We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we believe that achievement of these milestones will enable us to advance our gene therapy platform and position us to bring our drug candidate to commercialization.” In addition, GNPX this morning announced that it will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference in New York City at 3:00 PM ET on Tuesday, September 10, 2019. Genprex chairman and chief executive officer Rodney Varner will lead the presentation and will be available for one-on-one meetings. To set a meeting, contact the company at Investors@Genprex.com.
To view the full press releases, visit http://nnw.fm/AoZ8Q and http://nnw.fm/HIRm0
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com